RhumbLine Advisers’s BioTelemetry, Inc. BEAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-96,197
| Closed | -$6.93M | – | 3062 |
|
|
2020
Q4 | $6.93M | Sell |
96,197
-821
| -0.8% | -$43K | 0.01% | 1160 |
|
|
2020
Q3 | $4.42M | Sell |
97,018
-6,664
| -6% | -$279K | 0.01% | 1241 |
|
|
2020
Q2 | $4.68M | Sell |
103,682
-6,101
| -6% | -$273K | 0.01% | 1251 |
|
|
2020
Q1 | $4.23M | Buy |
109,783
+67
| +0.1% | +$3.08K | 0.01% | 1128 |
|
|
2019
Q4 | $5.08M | Buy |
109,716
+6,828
| +7% | +$296K | 0.01% | 1243 |
|
|
2019
Q3 | $4.19M | Buy |
102,888
+1,687
| +2% | +$72.8K | 0.01% | 1289 |
|
|
2019
Q2 | $4.87M | Buy |
101,201
+5,430
| +6% | +$285K | 0.01% | 1218 |
|
|
2019
Q1 | $6M | Buy |
95,771
+2,391
| +3% | +$164K | 0.01% | 1073 |
|
|
2018
Q4 | $5.58M | Buy |
93,380
+17,423
| +23% | +$1.05M | 0.01% | 1031 |
|
|
2018
Q3 | $4.89M | Sell |
75,957
-268
| -0.4% | -$15K | 0.01% | 1124 |
|
|
2018
Q2 | $3.43M | Buy |
76,225
+3,457
| +5% | +$138K | 0.01% | 1355 |
|
|
2018
Q1 | $2.26M | Buy |
72,768
+3,173
| +5% | +$104K | ﹤0.01% | 1535 |
|
|
2017
Q4 | $2.08M | Buy |
69,595
+12,692
| +22% | +$368K | ﹤0.01% | 1602 |
|
|
2017
Q3 | $1.88M | Buy |
56,903
+2,815
| +5% | +$97.5K | ﹤0.01% | 1653 |
|
|
2017
Q2 | $1.81M | Buy |
54,088
+1,158
| +2% | +$34.5K | ﹤0.01% | 1640 |
|
|
2017
Q1 | $1.53M | Buy |
52,930
+15,986
| +43% | +$396K | ﹤0.01% | 1702 |
|
|
2016
Q4 | $826K | Buy |
36,944
+2,013
| +6% | +$39.4K | ﹤0.01% | 1959 |
|
|
2016
Q3 | $649K | Buy |
34,931
+7,849
| +29% | +$148K | ﹤0.01% | 2051 |
|
|
2016
Q2 | $441K | Buy |
27,082
+1,190
| +5% | +$17.5K | ﹤0.01% | 2271 |
|
|
2016
Q1 | $302K | Buy |
25,892
+460
| +2% | +$5.14K | ﹤0.01% | 2528 |
|
|
2015
Q4 | $297K | Buy |
25,432
+1,965
| +8% | +$24.9K | ﹤0.01% | 2590 |
|
|
2015
Q3 | $287K | Buy |
23,467
+907
| +4% | +$11.6K | ﹤0.01% | 2571 |
|
|
2015
Q2 | $213K | Sell |
22,560
-5,655
| -20% | -$52.3K | ﹤0.01% | 2864 |
|
|
2015
Q1 | $250K | Buy |
28,215
+2,500
| +10% | +$25.3K | ﹤0.01% | 2712 |
|
|
2014
Q4 | $258K | Buy |
25,715
+1,725
| +7% | +$14.8K | ﹤0.01% | 2666 |
|
|
2014
Q3 | $161K | Hold |
23,990
| – | – | ﹤0.01% | 2833 |
|
|
2014
Q2 | $172K | Buy |
+23,990
| New | +$191K | ﹤0.01% | 2889 |
|
Other funds holding BEAT
RhumbLine Advisers's BEAT Position: Q1 2021 in Review
RhumbLine Advisers sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 96,197 shares — an estimated $6.93M sold.
RhumbLine Advisers first reported a position in BEAT in Q2 2014 and held it in 27 quarters. The position peaked at $6.93M in Q4 2020. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.
- RhumbLine Advisers reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
- RhumbLine Advisers sold 96,197 BioTelemetry, Inc. shares in Q1 2021, an estimated $6.93M.
- RhumbLine Advisers first reported a position in BioTelemetry, Inc. in Q2 2014 and held it in 27 quarters.
- RhumbLine Advisers's BioTelemetry, Inc. position peaked at $6.93M in Q4 2020.
- 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.
Based on RhumbLine Advisers's 13F filing for Q1 2021, filed 6 May 2021.